Signal

Suppliers are starting to get paid for the result their product delivers, not for the product itself. Salesforce now sells companies a help agent at 2 dollars a time: the company pays when the agent settles one of its customers' problems on its own, and nothing when that customer asks for a person or leaves unhappy. Intercom moved its Fin agent in March 2026 from charging per resolution to charging per outcome, 99 cents at most once per conversation, and Zendesk, the first to price AI agents this way in 2024, now has a separate AI model confirm every resolution it bills for. The same logic is reaching places where the product is a treatment or a social service. In Germany, the statutory health insurers agreed in April 2025 to pay for a gene therapy for haemophilia B according to each patient's treatment success, the first national deal of its kind in the country. In England, a 500 million pound fund for children's services will pay when school attainment, youth employment or reoffending measurably improve, and Japan's Cabinet Office opened a platform in October 2026 to spread its Pay for Success contracts. Buyers are pulling the same way. In G2's survey of a thousand business buyers, those preferring to pay per outcome rose from 11 to 19 percent in a year, and only 9 percent still call per-seat pricing the fairest. The risk now sits with the supplier, which is the point. Once payment follows the result, the invoice stops being a price list and becomes a record of what actually worked.

So what?

A supplier paid only when the problem is solved has to care about your result, and the bill becomes the record of what worked.

Evidence

Salesforce, 25 June 2026 (launch): Salesforce launched Agentforce Help Agent with pay-per-resolution pricing, generally available from July 2026. Customers are charged when the agent resolves an issue autonomously from start to finish, and not at all if the customer asks for a human or walks away unhappy. The pricing page lists 2 dollars per resolution.

CSL Behring, 2 April 2025 (news): CSL Behring and the GKV-Spitzenverband, the umbrella body of Germany's statutory health insurers, agreed a reimbursement price for the haemophilia B gene therapy Hemgenix under a success-based model applied for the first time at national level in Germany. The company's negotiator said reimbursement is coupled to the treatment success of the individual patient. The price and the success criteria were not disclosed.

UK Department for Culture, Media and Sport, 29 January 2026 (policy): The 500 million pound Better Futures Fund will support up to 200,000 children, young people and their families in England over ten years, mainly through Social Outcomes Partnerships in which government payments are tied to measurable improvements such as school attainment, youth employment and reduced reoffending. The first funding round ran in September 2026.

Worth asking

If you were paid only for the results your customers could measure, what would you do more of next month?

Try what this looks like

Fictional concepts this signal echoes

The vocabulary is evolving and will materialize here shortly.

Today's signals. Tomorrow's possibilities.

New science-fiction stories, emerging signals and essays exploring how life and work could change. Fresh perspectives and questions worth thinking about, delivered to your inbox.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Unsubscribe any time. Privacy Policy